Kenneth David Boffard

Summary

Affiliation: University of the Witwatersrand
Country: South Africa

Publications

  1. ncbi Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006
  2. ncbi Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
    Yoram Kluger
    Department of Surgery, Rambam Medical Center, POB 9602, Haifa 31096, Israel
    Crit Care 11:R85. 2007
  3. ncbi Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Maaloev, Denmark
    Crit Care 10:R104. 2006
  4. ncbi Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials
    Kenneth David Boffard
    Department of Surgery, Johannesburg Hospital, University of the Witwatersrand, South Africa
    J Trauma 59:8-15; discussion 15-8. 2005
  5. ncbi The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage
    Kenneth D Boffard
    Department of Surgery, Johannesburg Hospital, University of Witwatersrand, Johannesburg, South Africa
    Transfusion 49:240S-7S. 2009

Collaborators

Detail Information

Publications5

  1. ncbi Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
    Sandro B Rizoli
    Department of Surgery and Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5 Canada
    Crit Care 10:R178. 2006
    ....
  2. ncbi Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
    Yoram Kluger
    Department of Surgery, Rambam Medical Center, POB 9602, Haifa 31096, Israel
    Crit Care 11:R85. 2007
    ..We conducted a post hoc sub analysis of patients with TBI and severe blunt polytrauma enrolled into a prospective, international, double-blind, randomized, placebo-controlled study...
  3. ncbi Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
    Thomas Klitgaard
    Department of Biomodelling, Novo Nordisk A S, Maaloev, Denmark
    Crit Care 10:R104. 2006
    ..Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown...
  4. ncbi Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials
    Kenneth David Boffard
    Department of Surgery, Johannesburg Hospital, University of the Witwatersrand, South Africa
    J Trauma 59:8-15; discussion 15-8. 2005
    ....
  5. ncbi The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage
    Kenneth D Boffard
    Department of Surgery, Johannesburg Hospital, University of Witwatersrand, Johannesburg, South Africa
    Transfusion 49:240S-7S. 2009
    ..Recombinant activated factor VII (rFVIIa) offers theoretical possibilities of improving the coagulation profile...